Us diabetic neuropathy market

U.S. Diabetic Neuropathy Market, by Drug (Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine), Opioids (Tramadol, Tapentadol, Oksikodon), SNRIs (Duloxetine), Other Drugs (Capsaicin, Lidocaine, Botilinum Toxin)) by Type (Peripheral Neuropathy, Proximal Neuropathy, Autonomic Neuropathy, Focal Neuropathy), by Route of Administration (Oral, Topical, Injection (Intramuscular)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Nov 2022
CMI5356
160 Pages
Excel & Pdf
Pharmaceutical

Summary

Diabetes can damage nerves throughout the body. Diabetic neuropathy is the most common complication of diabetes mellitus numbness, pain in the hands, legs and feet, weakness of the muscles in the feet and hands, sharp pains, and insensitivity to pain or temperature changes are the common symptoms of diabetic neuropathy. Peripheral, autonomic, focal, and proximal neuropathy are the types of diabetic neuropathy. Among them, peripheral neuropathy is the most common type in which feet and legs are affected first then followed by hands and arms. Diabetic neuropathy can be extremely painful and cannot be cured. Pregabalin, amitriptyline and citalopram are some of the first-line treatment for painful diabetic neuropathy.

The U.S. diabetic neuropathy market is estimated to be valued at US$ 1,759.4 million in 2022 and is expected to exhibit a CAGR of 5.2% during the forecast period (2022-2030).

Figure 1. U.S. Diabetic Neuropathy Share (%), by Type, 2022

U.S. Diabetic Neuropathy Market - Driver

Increasing inorganic strategies such as product approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to boost the growth of the U.S. diabetic neuropathy market. For instance, in December 2019, Averitas Pharma, Inc., a pharmaceutical company, announced that they had received approval from U.S. Food and Drug Administration for QUTENZA, the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. QUTENZA is the first and only topical, non-systemic, non-opioid pain treatment for diabetic peripheral neuropathy. A single local topical treatment with QUTENZA may provide up to 3 months of relief from the nerve pain.

U.S. Diabetic Neuropathy Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 1,759.4 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.2%	2030 Value Projection:	US$ 2,635.9 Mn
Geographies covered:	U.S
Segments covered:	By Drug: Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine, Others (Oxcarbazepine, Topiramate and Others), Opioids (Tramadol, Tapentadol, Oksikodon), SNRIs (Duloxetine) Other Drugs (Capsaicin, Lidocaine, Botilinum Toxin) By Type: Peripheral Neuropathy, Proximal Neuropathy, Autonomic Neuropathy, Focal Neuropathy By Route of Administration: Oral, Topical, Injection (Intramuscular) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.
Growth Drivers:	Adoption of inorganic strategies such as drug approval by key regulatory authorities
Restraints & Challenges:	High cost treatment of diabetic neuropathy in the U.S.

Figure 2. U.S. Diabetic Neuropathy Share (%), by Route of Administration, 2022

U.S. Diabetic Neuropathy Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the U.S. diabetic neuropathy market due to the increasing risk of peripheral neuropathy from COVID-19. For instance, according to the data published in March 2022, by Washington University School of Medicine, COVID-19 patients are extremely at higher risk of experiencing symptoms of peripheral neuropathy, such as pain, numbness and tingling in the hands and feet, which, in turn, increased the sales of neuropathic treatment drugs, thus positively impacting the global diabetic neuropathy market growth.

U.S. Diabetic Neuropathy Market: Key Developments

Adoption of inorganic growth strategies such as drug approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to drive the U.S. diabetic neuropathy market. For instance, in July 2019, Alembic Pharmaceuticals Limited, a pharmaceutical company, announced that they had received an approval from U.S. Food and Drugs Administration for or Pregabalin capsules, an oral and extended-release tablets, which indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older.

U.S. Diabetic Neuropathy Market: Restraint

High cost treatment of diabetic neuropathy in the U.S. is expected to hamper the growth of the U.S. diabetic neuropathy market over the forecast period. For instance, in February 2020, according to the data published by National Center for Biotechnology Information, there is a significant increase in health care costs among a large number of patients with painful diabetic neuropathy (pDPN). The total median healthcare cost was US$ 16,795 in the first year after diagnosis and patients with painful diabetic neuropathy (pDPN) spent 3 times more as much on medications.

U.S. Diabetic Neuropathy Market - Key Players

Major players operating in the U.S. diabetic neuropathy market include Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.

Table of Content

Table of Contents

*Browse 12 market data tables and 26 figures on "U.S. Diabetic Neuropathy Market” - forecast to 2030

Segmentation

U.S. Diabetic Neuropathy Market, By Drug:
- Tricyclic Antidepressants
  - Amitriptyline
  - Nortyptyline
  - Imipramine
  - Desipramine
- SSRI
  - Paroxetine
  - Citalopram
- Anticonvulsants
  - Gabapentin
  - Pregabalin
  - Carbamazepine
  - Others (Oxcarbazepine, Topiramate and Others)
- Opioids
  - Tramadol
  - Tapentadol
  - Oksikodon
- SNRIs
  - Duloxetine
- Other Drugs
  - Capsaicin
  - Lidocaine
  - Botilinum Toxin
U.S. Diabetic Neuropathy Market, By Type:
- Peripheral Neuropathy
- Proximal Neuropathy
- Autonomic Neuropathy
- Focal Neuropathy
U.S. Diabetic Neuropathy Market, By Route of Administration:
- Oral
- Topical
- Injection (Intramuscular)
U.S. Diabetic Neuropathy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the U.S. diabetic neuropathy market during the forecast period (2022-2030)?

The U.S. diabetic neuropathy market size is estimated to be valued at US$ 1,759.4 million in 2022 and is expected to exhibit a CAGR of 5.2% between 2022 and 2030

What are the major factors driving the market growth?

Adoption of inorganic strategies such as drug approval by key regulatory authorities such as the U.S. Food and Drug Administration is expected to drive the market

Which is the leading type segment in the market?

Peripheral neuropathy is the leading type segment in the market

What are the key factors hampering growth of the market?

High cost treatment of diabetic neuropathy in the U.S. is expected to hamper the market.

Which are the major players operating in the market?

Major players operating in the market include Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.